Clinical Trial Update: Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients [NA]

View source ↗

Summary

A terminated clinical trial evaluated omega-3 polyunsaturated fatty acids or magnesium in obese women with polycystic ovary syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Polycystic Ovary Syndrome

Drugs mentioned

• Magnesium (magnesium)
• Omega-3 polyunsaturated fatty acids (omega-3 polyunsaturated fatty acids)

Snippet

Sponsor: Coordinación de Investigación en Salud, Mexico | Conditions: Polycystic Ovary Syndrome, Obesity | NA | Status: TERMINATED